tariffs
Trump’s Most Favored Nation Policy and EU Generics: Recent Developments
Trump; Most Favored Nation policy; EU generics; drug pricing; tariffs; pharma
Pfizer CEO Holds ‘Extremely Productive’ Talks With Trump Administration Amid MFN Pricing and Tariff Threats
Pfizer; Albert Bourla; Trump administration; Most Favored Nation (MFN) pricing; drug pricing; tariffs; pharmaceutical industry; direct-to-consumer (DTC) sales; policy negotiation; Robert F. Kennedy Jr.; Mehmet Oz; PhRMA
AstraZeneca Unveils $50 Billion U.S. Investment, Including Major Manufacturing Facility in Virginia
AstraZeneca; investment; United States; Virginia plant; manufacturing; R&D; tariffs; chronic diseases; job creation; pharmaceuticals
Big Pharma Braces for Potential 200% US Tariffs Amid Uncertainty
pharmaceutical industry; tariffs; Donald Trump; supply chains; onshoring; drug prices; manufacturing; healthcare system
Sanofi Announces $20 Billion US Investment Over Five Years
Sanofi; $20 billion investment; US pharmaceutical industry; manufacturing; research and development; tariffs; job creation; Big Pharma; domestic partnerships
Pfizer’s Bourla is ‘cautiously optimistic’ on tariffs, says M&A is on the table
Bourla, M&A, Pfizer, United States, TNFRSF19 gene, Policy, tariffs
Trump Tariffs Could Delay Regulatory Filings for Half of Biotech Companies
Tariffs, Biotechnology, Regulatory filings, Manufacturing costs, Supply chain disruption
U.S. Hospitals Urge Trump to Exempt Medical Supplies and Pharmaceuticals from New Tariffs
Tariffs, medical supplies, pharmaceuticals, American Hospital Association, China, Mexico, Canada, healthcare costs, supply chain disruption, patient safety